Publications by authors named "Nicholas Pulliam"

Claim this Profile
M
Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing.
Elisabet Zapatero-Solana, Yan Ding, Nicholas Pulliam, Alfonso de Dios, Maria Jesus Ortiz-Ruiz

Int J Mol Sci· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.
Shripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao, Weihua Shen, Nicholas Pulliam

Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy.
Severine Isabelle Gharbi, Laura A Pelletier, Alfonso Espada, Jesus Gutiérrez, Sonia Maria Gutiérrez Sanfeliciano, Nicholas Pulliam

NPJ Breast Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy.
Severine Isabelle Gharbi, Laura A Pelletier, Alfonso Espada, Jesus Gutiérrez, Sonia Maria Gutiérrez Sanfeliciano, Nicholas Pulliam

NPJ Breast Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells.
Nicholas Pulliam, Jessica Tang, Weini Wang, Fang Fang, Riddhi Sood

Cancers (Basel)· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion.
Jessica Tang, Nicholas Pulliam, Ali Özeş, Aaron Buechlein, Ning Ding

Mol Cancer Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Nicholas Pulliam, Fang Fang, Ali R Ozes, Jessica Tang, Adeoluwa Adewuyi

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
James Haley, Sunil Tomar, Nicholas Pulliam, Sen Xiong, Susan M Perkins

Oncotarget· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis